Table 1. Summary of Patient and Treatment Characteristics.
| Characteristic | Before PS Matching | After PS Matching | ||||
|---|---|---|---|---|---|---|
| ESRT (n = 1195) | ART (n = 371) | P Value | ESRT (n = 366) | ART (n = 366) | P Value | |
| Age at surgery, median (IQR), y | 60.0 (55.0-64.7) | 60.0 (55.2-65.0) | .44a | 61.0 (54.6-65.3) | 60.0 (55.0-65.0) | .90a |
| Year of surgery, median (IQR) | 2002 (1998-2006) | 2006 (2000-2008) | <.001a | 2005 (2001-2007) | 2006 (2000-2008) | .29a |
| Follow-up since surgery, median (IQR), mo | 92.3 (55.3-134) | 65.4 (40-107) | <.001a | 73.3 (44.9-106.6) | 65.8 (40-107) | .22a |
| Pathological T stage, No. (%)b | ||||||
| T2 | 553 (46.3) | 98 (26.4) | <.001c | 109 (29.8) | 98 (26.8) | .63c |
| T3a | 435 (35.4) | 183 (49.3) | 170 (46.4) | 181 (49.5) | ||
| T3b | 207 (17.3) | 90 (24.3) | 87 (23.8) | 87 (23.8) | ||
| Surgical Gleason score, No. (%) | ||||||
| 6 | 248 (20.8) | 50 (13.5) | <.001c | 33 (9.0) | 50 (13.7) | .18c |
| 7 | 722 (60.4) | 214 (57.7) | 209 (57.1) | 210 (57.4) | ||
| 8 | 108 (9.0) | 46 (12.4) | 54 (14.8) | 45 (12.3) | ||
| 9 | 116 (9.7) | 61 (16.4) | 70 (19.1) | 61 (16.7) | ||
| 10 | 1 (0.1) | 0 (0) | ||||
| Margin status, No. (%) | ||||||
| Positive | 721 (60.3) | 315 (84.9) | <.001c | 318 (86.9) | 313 (85.8) | .67c |
| Negative | 462 (38.7) | 53 (14.3) | 48 (13.1) | 53 (14.5) | ||
| Unknown | 12 (1.0) | 3 (0.8) | ||||
| Time from surgery to RT, median (IQR), mo | 22.9 (8.5-44.3) | 4.4 (3.5-6.4) | <.001a | 14.1 (4.9-31.2) | 4.5 (3.5-6.4) | <.001a |
| Follow-up since RT, median (IQR), mo | 55.9 (26.6-96.1) | 58.4 (32.0-101.2) | .08a | 49.2 (22.2-80.0) | 59.2 (32.0-101.2) | <.001a |
| Pre-RT PSA level, median (IQR), ng/mL | 0.3 (0.2-0.4) | <0.1 | NA | 0.3 (0.2-0.4) | <0.1 | NA |
| RT technique, No. (%) | ||||||
| 2-D | 245 (20.5) | 69 (18.6) | <.001c | 58 (15.8) | 69 (18.9) | .16c |
| 3-D CRT | 311 (26.0) | 64 (17.3) | 70 (19.1) | 63 (17.2) | ||
| IMRT | 436 (36.5) | 174 (46.9) | 192 (52.5) | 171 (46.7) | ||
| Unknown | 203 (17.0) | 64 (17.2) | 46 (12.6) | 63 (17.2) | ||
| RT node coverage, No. (%) | ||||||
| Yes | 141 (11.8) | 43 (11.6) | >.99c | 47 (12.8) | 43 (11.7) | .74c |
| No | 1054 (88.2) | 328 (88.4) | 319 (87.2) | 323 (88.3) | ||
| RT dose to prostate fossa, median (IQR), Gy | 64.8 (64.8-68.1) | 64.8 (61.2-66.0) | <.001a | 66.0 (64.8-70.0) | 64.8 (61.2-66.0) | <.001a |
| RT duration, median (IQR), d | 50 (48-52) | 49 (46-50) | <.001a | 50 (48-52) | 49 (46-50) | <.001a |
| Postoperative ADT, No. (%) | ||||||
| Yes | 135 (11.3) | 23 (6.2) | .004c | 19 (5.2) | 23 (6.3) | .63c |
| No | 1060 (88.7) | 348 (93.8) | 347 (94.8) | 343 (93.7) | ||
Abbreviations: ADT, androgen deprivation therapy; ART, adjuvant radiation therapy; ESRT, early-salvage radiation therapy; IMRT, intensity-modulated radiation therapy; IQR, interquartile range; PS, propensity score; PSA, prostate-specific antigen; RT, radiation therapy; 2-D, 2-dimensional; 3-D CRT, 3-dimensional conformal radiotherapy.
SI conversion factor: To convert PSA to micrograms per liter, multiply by 1.0; to convert gray to rad, multiply by 100.
a
Calculated using the Wilcoxon rank sum test.
b
All patients with stage T2 had positive surgical margins.
c
Calculated using the Fisher exact test.